173 related articles for article (PubMed ID: 22810479)
1. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.
Ren J; Li G; Ge J; Li X; Zhao Y
Dis Colon Rectum; 2012 Aug; 55(8):913-23. PubMed ID: 22810479
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
3. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.
Zahrani A; Kandil M; Badar T; Abdelsalam M; Al-Faiar A; Ismail A
Tumori; 2014; 100(1):75-9. PubMed ID: 24675495
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
6. Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.
Rui YY; Zhang D; Zhou ZG; Wang C; Yang L; Yu YY; Chen HN
PLoS One; 2013; 8(10):e77901. PubMed ID: 24205021
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer.
Kazmi HR; Chandra A; Nigam J; Noushif M; Parmar D; Gupta V
Dig Surg; 2013; 30(3):233-9. PubMed ID: 23838952
[TBL] [Abstract][Full Text] [Related]
8. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis.
Rui Y; Wang C; Zhou Z; Zhong X; Yu Y
Hepatogastroenterology; 2015; 62(137):19-24. PubMed ID: 25911860
[TBL] [Abstract][Full Text] [Related]
9. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.
Pérez-Ruiz E; Rueda A; Pereda T; Alcaide J; Bautista D; Rivas-Ruiz F; Villatoro R; Pérez D; Redondo M
Tumour Biol; 2012 Dec; 33(6):1829-35. PubMed ID: 22791568
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
11. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
Chen J; Ye Y; Sun H; Shi G
Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
[TBL] [Abstract][Full Text] [Related]
12. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.
Qiu LX; Mao C; Zhang J; Zhu XD; Liao RY; Xue K; Li J; Chen Q
Eur J Cancer; 2010 Oct; 46(15):2781-7. PubMed ID: 20580219
[TBL] [Abstract][Full Text] [Related]
14. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
[TBL] [Abstract][Full Text] [Related]
15. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Grassi N; Latteri MA; La Farina M; Albanese I; Dardanoni G; Salerno S; Tomasino RM; Labianca R; Gebbia N; Russo A
Ann Oncol; 2002 Sep; 13(9):1438-46. PubMed ID: 12196370
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.
Conlin A; Smith G; Carey FA; Wolf CR; Steele RJ
Gut; 2005 Sep; 54(9):1283-6. PubMed ID: 15843421
[TBL] [Abstract][Full Text] [Related]
19. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.
Tao LY; Zhang LF; Xiu DR; Yuan CH; Ma ZL; Jiang B
World J Surg Oncol; 2016 May; 14():146. PubMed ID: 27183870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]